RESISTANT CELL LINES AND METHODS OF TREATING CANCER USING COMBINATION OF HDAC6 INHIBITOR AND BTK PATHWAY INHIBITOR

摘要

Provided herein is a new therapeutic regimen comprising an HDAC6 inhibitor and a BKT inhibitor for the treatment of lymphoma. More specifically, the regimen comprises treatment with ACY-1215 and ibrutinib. Furthermore, the invention provides a lymphoma cell line resistant to the HDAC6 selective inhibition.